Sandoz Expects ‘Trough Year’ In 2023 As It Counts Cost Of Spinoff

Novartis management has set out its expectations for 2023 to be a “trough year” for Sandoz in terms of its core margin, as the generics and biosimilars unit is spun out into a separate company from its parent business. The firm cited the costs associated with the spinoff, as well as current inflationary pressures, as being behind the expected dip.